FDA sanctions don't kill a business

Share this article:

FDA sanctions may not be the end for a drugmaker. Bloomberg reports that India's Wockhardt Ltd., which was hit with enough violations that the FDA banned products from two of its plants, expects sales to hit $1 billion in 2017, thanks to domestic (as in non-US) sales.

Bloomberg says the firm has become a possible M&A target for peer and neighbor Lupin, Ltd.

“What's attractive about this company, in spite of the import alerts, is its presence in India, the US and Europe,” CIMB securities analyst Prakash Agarwal tells Bloomberg.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.

Sanofi wants greater MS role

The plan is to bring in-house products to the market as well as through acquisitions.

Mylan buys branded and generic Arixtra

The $225-million deal will give Mylan one of two generics for the deep vein thrombosis drug.